Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom

Abstract

AbstractAimTo examine trends of second‐line glucose‐lowering therapies among patients with type 2 diabetes (T2D) initiating first‐line metformin in the United States and the United Kingdom, overall and by subgroups of cardiovascular disease (CVD) and calendar time.MethodsUsing the US Optum Clinformatics and the UK Clinical Practice Research Datalink, we identified adults with T2D who initiated first‐line metformin or sulphonylurea monotherapy, separately, from 2013 to 2019. Within both cohorts, we identified patterns of second‐line medications through June 2021. We stratified patterns by CVD and calendar time to investigate the impact of rapidly evolving treatment guidelines.ResultsWe identified 148 511 and 169 316 patients initiating treatment with metformin monotherapy in the United States and the United Kingdom, respectively. Throughout the study period, sulphonylureas and dipeptidyl peptidase‐4 inhibitors were the most frequently initiated second‐line medications in the United States (43.4% and 18.2%, respectively) and the United Kingdom (42.5% and 35.8%, respectively). After 2018, sodium‐glucose co‐transporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonists were more commonly used as second‐line agents in the United States and the United Kingdom, although these agents were not preferentially prescribed among patients with CVD. Initiation of first‐line sulphonylureas was much less common, and most sulphonylurea initiators had metformin added as the second‐line agent.ConclusionsThis international cohort study shows that sulphonylureas remain the most common second‐line medications prescribed following metformin in both the United States and the United Kingdom. Despite recommendations, the use of newer glucose‐lowering therapies with cardiovascular benefits remains low.